About: NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.15 (-6.80%)
NCEL NASDAQ NewcelX Ltd.
NewcelX Ltd. share price
NCEL price activity
Last Price
$3.150
Change (24hr)
-0.23 USD (-6.80%)
Volume
2.46K
Volume (4w avg)
-
Open
$3.16
Day Range
$3.13 - $3.38
Previous Close
$3.38
Last Trade
18 Sep, 8:00 pm GMT+0
Delayed
18 Sep, 8:00 pm GMT+0
NCEL price performance
Delayed
18 Sep, 8:00 pm GMT+0
NCEL Market Signals